Involvement of bradykinin B1 and B2 receptors in human PMN elastase release and increase in endothelial cell monolayer permeability

Immunopharmacology

Volumn 33, Issue 1-3, 1996, Pages 325-329

  Carl, Virginia S ^a   Moore, Ernest E ^a   Moore, Frederick A ^a   Whalley, Eric T ^b  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b Departments of New Leads Chemistry and Pharmacology   (United States)

Author keywords

B1 B2 receptor; elastase; human PMN

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR AGONIST; CP 0345; CP 0597; ELASTASE INHIBITOR; IODINE 125; KALLIDIN[1-9]; LEUKOCYTE ELASTASE; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG; BRADYKININ RECEPTOR; DRUG DERIVATIVE; KALLIDIN; KALLIDIN, DES ARG(10); KALLIDIN, DES-ARG(10)-; METHOXYSUCCINYL ALANYL ALANYL PROLYL VALINE CHLOROMETHYL KETONE; METHOXYSUCCINYL-ALANYL-ALANYL-PROLYL-VALINE CHLOROMETHYL KETONE; PEPTIDE CHLOROMETHYL KETONE; SERINE PROTEINASE INHIBITOR;

CONFERENCE PAPER; CONTROLLED STUDY; DRUG ANTAGONISM; ENDOTHELIUM CELL; ENZYME RELEASE; HUMAN; HUMAN CELL; INFLAMMATION; MEDIATOR; MEMBRANE PERMEABILITY; MONOLAYER CULTURE; NEUTROPHIL; PRIORITY JOURNAL; UMBILICAL VEIN; ARTICLE; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; PERMEABILITY; SECRETION; VASCULAR ENDOTHELIUM;

AMINO ACID CHLOROMETHYL KETONES; BRADYKININ; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; KALLIDIN; LEUKOCYTE ELASTASE; NEUTROPHILS; PERMEABILITY; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; SERINE PROTEINASE INHIBITORS;

EID: 0030153316     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(96)00055-0     Document Type: Conference Paper

References (11)

1. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins-kallikreins, kininogens and kininases. Pharmacol Rev 1992; 44: 1-80.
2. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1-46.
3. 1 receptors: a review. Immunopharmacology 1995; 30: 1-26.
4. Figueroa CD, MacIver AG, Bhoola KD. Identification of a tissue kallikrein in human polymorphonuclear leucocytes. Br J Haematol 1989; 72: 321-328.
5. Figueroa CD, Henderson LM, Kaufmann J, De La Cadena RA, Colman RW, Muller-Esterl W, Bhoola KD. Immunovisualization of high (HK) and low (LK) molecular weight kininogens on isolated human neutrophils. Blood 1992; 79(3): 754-759.
6. 2 receptors in target cells of kinin action. Visualization of the receptor protein in A431 cells, neutrophils, and kidney sections. Braz J Med Biol Res 1994; 27: 1739-1756.
7. Haslett C, Guthrie LA, Kopaniak MM, Johnston RBJ, Henson PM. Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol 1985; 119(1): 101-110.
8. Goodfellow VS, Marathe MV, Kuhlman KG, Fitzpatrick TD, Cuadrado D, Hanson W, Zuzack JS, Ross SE, Wieczorek M, Burkard M, Whalley ET. Bradykinin receptor antagonists containing n-substituted amino acids: in vivo B2 and B1 receptor antagonist activity. J Med Chem 1996; (in press).
9. 1 receptor antagonist. Eur J Pharmacol 1991; 205: 217-218.
10. Stewart JM, Gera L, Whalley ET, Hanson W, McCullough R. A new generation of bradykinin antagonists. Immunopharmacology: 33: 51-60.
11. Blodgett JK, Allen LG, Goodfellow VS, Loy SD, marathe MV, McLeod DA, Spruce LW, Whalley ET, Cheronis JC. Development of dual action heterodimeric compounds containing bradykinin antagonist activity, in Hodges RS, Smith JA (eds): Proceedings of the Thriteenth American Peptide Symposiums Peptides: Chemistry, Structure and Biology. Leiden, Escom, 1994, pp 353-355.